All In MedTech

FDA Clearance Tracker · P250024-S001

Trilogy Transcatheter Heart Valve System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 18, 2026

Approved

Time to decision

32 days

Received Apr 16, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P250024-S001
Device name
Trilogy Transcatheter Heart Valve System
Applicant location
Irvine, CA
Received
Apr 16, 2026
Decided
May 18, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P250024

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

approval for the protocol for the Continued Follow-up of the Premarket Cohort post-approval study (PAS)

Source documents

Other decisions for JenaValve Technology, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.